Published in Onco Targets Ther on March 09, 2016
The Efficacy of Brucea javanica Oil Emulsion Injection as Adjunctive Therapy for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis. Evid Based Complement Alternat Med (2016) 0.75
The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China. Onco Targets Ther (2016) 0.75
Combination Therapy of Gefitinib and Korean Herbal Medicines Could be a Beneficial Option for Patients with Non-Small-Cell Lung Cancer. J Pharmacopuncture (2016) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol (2003) 15.10
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature (1984) 14.21
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 10.74
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A (2008) 8.08
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res (2006) 6.91
Molecular cloning and expression of human hepatocyte growth factor. Nature (1989) 6.91
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene (2008) 6.82
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A (2005) 6.82
The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer (2001) 5.96
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol (2012) 5.82
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res (2007) 5.45
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol (2003) 4.05
High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res (2004) 3.66
Report of cancer incidence and mortality in China, 2010. Ann Transl Med (2014) 3.60
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol (2002) 3.53
Management of non-small-cell lung cancer: recent developments. Lancet (2013) 3.51
Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer (2006) 3.15
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med (2008) 3.00
Common and distinct elements in cellular signaling via EGF and FGF receptors. Science (2004) 2.99
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol (2012) 2.98
United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res (2004) 2.43
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol (2002) 2.25
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res (2007) 2.07
Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J Thorac Oncol (2008) 1.88
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol (2015) 1.76
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol (2006) 1.58
Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer (2007) 1.34
Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res (2002) 1.27
A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res (2011) 1.27
Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer (2008) 1.24
The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol (2005) 1.20
EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol (2009) 1.18
Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet (2005) 1.14
Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica (2004) 1.09
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Clin Cancer Res (2005) 1.09
Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer. Drug Saf (2004) 1.08
HKI-272 in non small cell lung cancer. Clin Cancer Res (2007) 1.07
Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. J Thorac Oncol (2009) 1.06
Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor. Oncogene (2012) 1.04
Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer (2005) 1.03
Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. Cell Res (2005) 1.03
Survival among Chinese women with lung cancer in Singapore: a comparison by stage, histology and smoking status. Lung Cancer (2003) 0.96
Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol (2008) 0.96
Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. Future Oncol (2007) 0.95
Lung cancer with a single brain metastasis: therapeutic options. Tumori (1990) 0.90
Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res (2012) 0.89
Introducing music therapy in hospice and palliative care: an overview of one hospice's experience. Home Healthc Nurse (2010) 0.89
Gefitinib in non-small cell lung cancer. Expert Opin Pharmacother (2005) 0.88
Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer. Asian Pac J Cancer Prev (2014) 0.88
Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. Asia Pac J Clin Oncol (2012) 0.86
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics (2011) 0.86
Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet (2001) 0.85
[Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi (2012) 0.82
Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. Int J Pharm (2007) 0.82
Outdoor air pollution: a global perspective. J Occup Environ Med (2014) 0.82
Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity. Nagoya J Med Sci (2012) 0.81
Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer (2003) 0.81
Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan. Radiat Oncol (2015) 0.81
Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors. Future Oncol (2015) 0.80
[Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial]. Ai Zheng (2005) 0.80
[The short-term observation of Shenqifuzheng injection combined with NP chemotherapy in treating elder patients with advanced non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi (2007) 0.79
Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer. Clin Lung Cancer (2012) 0.79
Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors. Onco Targets Ther (2015) 0.78
[Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)]. Zhonghua Zhong Liu Za Zhi (2009) 0.78
Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer. Curr Cancer Drug Targets (2015) 0.77
[Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma]. Zhonghua Yi Xue Za Zhi (2014) 0.77
Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature. Oncol Lett (2015) 0.76
The role of pemetrexed in second-line chemotherapy for advanced non-small cell lung cancer. Curr Drug Targets (2010) 0.76
The relative bioavailability of gefitinib administered by granular formulation. Cancer Chemother Pharmacol (2007) 0.76
Complementary therapy: perceptions of older people with lung or colorectal cancer. Int J Palliat Nurs (2013) 0.76
Gefitinib: current status in the treatment of non-small cell lung cancer. Drugs Today (Barc) (2004) 0.76
Research unveils the 'who' and 'why' of gefitinib. J Natl Cancer Inst (2004) 0.76
[Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors]. Yao Xue Xue Bao (2013) 0.76
Study of the methylation patterns of the EGFR gene promoter in non-small cell lung cancer. Genet Mol Res (2015) 0.76